Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections.
about
A new strategy to fight antimicrobial resistance: the revival of old antibiotics"Stormy waters ahead": global emergence of carbapenemasesAntibacterial Discovery and Development: From Gene to Product and BackInhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road aheadImmunomodulation in sepsis: the role of endotoxin removal by polymyxin B-immobilized cartridgeWhat is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regressionColistimethate sodium for the treatment of chronic pulmonary infection in cystic fibrosis: an evidence-based review of its place in therapySelective labelling and eradication of antibiotic-tolerant bacterial populations in Pseudomonas aeruginosa biofilms.Renal and neurological side effects of colistin in critically ill patientsDiscovery of a Novel Class of Boron-Based Antibacterials with Activity against Gram-Negative BacteriaAntimicrobial Peptide Resistance of Vibrio cholerae Results from an LPS Modification Pathway Related to Nonribosomal Peptide SynthetasesThe structure of apo ArnA features an unexpected central binding pocket and provides an explanation for enzymatic cooperativityColistin in Pig Production: Chemistry, Mechanism of Antibacterial Action, Microbial Resistance Emergence, and One Health PerspectivesColistin for lung infection: an updateAdaptive resistance to the "last hope" antibiotics polymyxin B and colistin in Pseudomonas aeruginosa is mediated by the novel two-component regulatory system ParR-ParSCell Based Drug Delivery: Micrococcus luteus Loaded Neutrophils as Chlorhexidine Delivery Vehicles in a Mouse Model of Liver Abscesses in CattleDynamic Computational Model of Symptomatic Bacteremia to Inform Bacterial Separation Treatment RequirementsBiodiversity of genes encoding anti-microbial traits within plant associated microbesA lipoprotein/β-barrel complex monitors lipopolysaccharide integrity transducing information across the outer membraneLipopolysaccharide transport to the cell surface: periplasmic transport and assembly into the outer membrane.Probing the penetration of antimicrobial polymyxin lipopeptides into gram-negative bacteriaNew colistin population pharmacokinetic data in critically ill patients suggesting an alternative loading dose rationale.Squalamine: an appropriate strategy against the emergence of multidrug resistant gram-negative bacteria?Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections.Polymyxin B identified as an inhibitor of alternative NADH dehydrogenase and malate: quinone oxidoreductase from the Gram-positive bacterium Mycobacterium smegmatis.Nonclonal emergence of colistin-resistant Klebsiella pneumoniae isolates from blood samples in South Korea.Mapping residue-specific contacts of polymyxin B with lipopolysaccharide by saturation transfer difference NMR: insights into outer-membrane disruption and endotoxin neutralization.Teaching 'old' polymyxins new tricks: new-generation lipopeptides targeting gram-negative 'superbugs'.Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models.Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of AmericaMultidrug resistant acinetobacter.Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort studyA Study of 24 Patients with Colistin-Resistant Gram-negative Isolates in a Tertiary Care Hospital in South India.Colistin-induced nephrotoxicity in mice involves the mitochondrial, death receptor, and endoplasmic reticulum pathways.Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 2. ColistinAttenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model.Colistin in the 21st century.Activities of colistin- and minocycline-based combinations against extensive drug resistant Acinetobacter baumannii isolates from intensive care unit patients.Self-assembly behavior of colistin and its prodrug colistin methanesulfonate: implications for solution stability and solubilization.Evaluating the stability of colistin and colistin methanesulphonate in human plasma under different conditions of storage
P2860
Q21131083-DDDF8810-31A0-4091-9E86-70F4C74A0CE0Q21131125-9686723B-F6F1-4AA9-AD13-95DCDD2416E6Q26784492-BD98FB3E-12D0-457B-ABFC-2C7489CEDA87Q26822988-21ECA9AB-0203-4A9B-8477-635F0C1B0C10Q26830445-CD781170-180E-4226-9B36-185AF7DE46AFQ26999921-5A9E7903-15F3-47F2-B616-1D0F33B3DA71Q27014993-03B27F43-8D7A-4FDE-96E6-C1E236C14178Q27331155-5932E26A-2503-44E7-A90D-5EE5479C062CQ27499294-8E3FD380-E4C6-450F-85E1-2900A730DF14Q27675792-48CFD85B-07D8-4FA1-981C-E95F6DDF57A0Q27684837-7207F041-58D0-4605-A6D6-87999DCB3AA5Q27698393-C7985EDE-2E43-46DF-8F0F-55A850F6CB8FQ28076261-A71A727B-0CB8-41F8-836A-23FC4F7AA0F4Q28082041-459A3EF3-0A81-49DA-B25A-BEDF341A66A8Q28493107-2E32070C-05C0-4151-AD2E-1C4117BC37F0Q28547454-7F331F8A-E6A4-41C7-975C-529C8BD0F82AQ28554305-D46E4412-F7F9-4FCB-AE73-A8E6FCA9DE92Q28649879-6B192D6C-BF27-474D-8DA8-35A8956C50B0Q30152775-116F6EA8-E543-45D6-A536-D7CF458E664FQ30152829-22ACF078-0A72-40DA-9C90-4228F6A8F25DQ30576597-5A5B6CCF-667D-4D37-8505-693CD37D7F94Q30856181-B042CCE5-BA8B-4E98-B350-A140563729C5Q33354067-959136E6-C8FC-4D2C-9F80-C80CB2C04DC8Q33416170-60797705-3D73-48D1-AF5B-E8671A0A9200Q33476065-AFC6302D-3FEF-4743-AB32-16313085165CQ33559059-23474897-B347-423C-8E23-6122A69F7742Q33648928-CC03D3AC-3FD3-419D-9B8A-15D67BD4DF82Q33662378-0EAD490F-805A-4537-B3D8-B44E08B937CFQ33676366-E750A7FF-A25A-489B-A356-92261A5F3E14Q33688646-75EFBD48-F453-4E9A-A60C-F36B7ED2A306Q33711902-6CF22F1A-CC9C-4934-8400-D7332A94B74EQ33751736-A02FEBE2-F4FC-485E-918B-F81075D66277Q33755535-B54B736C-7031-470A-881F-428FA97B3AA9Q33798324-FBADA6EE-861A-4B8E-9212-C045459F5459Q33798554-2FA66378-44BD-433D-8321-7D1FD4B43BDEQ33826267-E1A33F9D-9575-418D-8B0C-24273425CAEEQ33847509-4114B01A-1482-452A-BA40-1B930A641F6FQ33882361-5718FA67-8ADF-48E1-800D-2804E7237DE8Q33895471-015BD747-EE3B-4514-99D2-46847CDBF1B4Q33902534-3B5DBD6C-6EBD-4838-B8E8-347558416E26
P2860
Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections.
description
2006 nî lūn-bûn
@nan
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Colistin: the re-emerging anti ...... negative bacterial infections.
@ast
Colistin: the re-emerging anti ...... negative bacterial infections.
@en
Colistin: the re-emerging anti ...... negative bacterial infections.
@nl
type
label
Colistin: the re-emerging anti ...... negative bacterial infections.
@ast
Colistin: the re-emerging anti ...... negative bacterial infections.
@en
Colistin: the re-emerging anti ...... negative bacterial infections.
@nl
prefLabel
Colistin: the re-emerging anti ...... negative bacterial infections.
@ast
Colistin: the re-emerging anti ...... negative bacterial infections.
@en
Colistin: the re-emerging anti ...... negative bacterial infections.
@nl
P2093
P50
P921
P1476
Colistin: the re-emerging anti ...... negative bacterial infections.
@en
P2093
Craig R Rayner
John D Turnidge
Kingsley Coulthard
P304
P356
10.1016/S1473-3099(06)70580-1
P577
2006-09-01T00:00:00Z